Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

CStone Approved to Start US Trial of anti-PD-L1 in Lymphoma

publication date: Aug 31, 2020

CStone Pharma of Suzhou has been approved to start a US Phase II trial of its PD-L1 mAb in patients with a relatively rare, difficult-to-treat form of lymphoma. Cstone's sugemalimab (CS1001) will be tested as a monotherapy in relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma (R/R ENKTL). The disease has a one-year survival rate of less than 20% in currently available treatments, but a 72% rate with sugemalimab. The US trial will extend a similar test already underway in China. More details....

Stock Symbol: (HK: 2616)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.